Skip to content

OnKure Therapeutics, Inc. OKUR Other Non-Current Liabilities

Other Non-Current Liabilities at other companies

Pfizer logo
PfizerPFE
$14.2B+6.8%
Eikon Therapeutics, Inc.
 logo
Eikon Therapeutics, Inc. EIKN
$10M
Replimune Group logo
Replimune GroupREPL
$693K-45.3%
Erasca, Inc. logo
Erasca, Inc.ERAS
$340K+35.5%
Arcus Biosciences logo
Arcus BiosciencesRCUS
$119M-28.3%
Incyte logo
IncyteINCY
$126.59M-27.9%

Other financials

Income statement

See full
Revenue-
Operating income-$15.6M+8.1%
Net income-$15.2M+4.8%
EPS (diluted)-$1.11+6.7%

Balance sheet

See full
Cash & equivalents$192.1M+98.7%
Total debt$409.0K-57.2%
Total equity$184.4M+103%
Total assets$198.7M+98.9%

Cash flow

See full
Operating cash flow-$12.9M+7.6%
CapEx$5.0K-72.2%
Free cash flow-$12.9M+7.7%

Valuation

See full
Market cap$184.2M+72.6%
Enterprise value-$7.49M-127%

Returns & leverage

See full
Return on equity-42.7%
Debt / equity0.0×
Current ratio13.8×+2.6×

Where this comes from

Reported directly by OnKure Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:OtherLiabilitiesNoncurrent.

The official record: OnKure Therapeutics, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about OnKure Therapeutics, Inc.'s other non-current liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is OnKure Therapeutics, Inc.'s other non-current liabilities?
OnKure Therapeutics, Inc. (OKUR) reported other non-current liabilities of $12K in Q1 2026.
How has OnKure Therapeutics, Inc.'s other non-current liabilities changed year-over-year?
OnKure Therapeutics, Inc.'s other non-current liabilities decreased by 70.0% year-over-year, from $40K to $12K.
What does other non-current liabilities mean?
Miscellaneous long-term obligations not classified in specific categories — pension liabilities, environmental remediation, and other long-term accruals.